Aktienanalyse zu Cryo-Cell International Inc (CCEL)CCELCryo-Cell International Inc

Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 240,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. It operates in the Healthcare sector (SERVICES-MISC HEALTH & ALLIED SERVICES, NEC industry).

Cryo-Cell International is currently not a good buy due to mixed financial results and compliance risks. The stock has a current price of $5.35, and while it has shown a strong year-to-date change of +55.98%, it also faces significant challenges, including a negative forward P/E ratio of 2000 and a recent decline in revenue. The company is under scrutiny for compliance with NYSE American listing requirements, which could pose risks to its future performance.